Research programme: SIRT-1 activators - RezGen5 Ltd

Drug Profile

Research programme: SIRT-1 activators - RezGen5 Ltd

Alternative Names: RezGen5

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeoMedigen
  • Developer RezGen5 Ltd
  • Class Carotenoids; Nicotinic-acids; Polyphenols; Small molecules; Stilbenes; Zinc compounds
  • Mechanism of Action Cell cycle inhibitors; DNA repair enzyme stimulants; Free radical scavengers; Glycolysis inhibitors; Immunostimulants; Inflammation mediator inhibitors; Neuron modulators; Nicotinamide adenine dinucleotide modulators; Poly(ADP-ribose) polymerase modulators; SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Cardiovascular disorders; Neurodegenerative disorders; Obesity; Skin disorders; Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Bermuda
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Bermuda
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Bermuda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top